Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
Pfizer announced positive topline results from the Phase 3 MagnetisMM-5 study, where ELREXFIO monotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival versus standard of care. The trial met its primary endpoint at the interim analysis with 497 patients enrolled across 26 countries, showing a safety profile consistent with previous experience.
Key figures
- Drug Name
- ELREXFIO (elranatamab)
- Phase Of Trial
- Phase 3
- Trial countries
- 26
- Patients enrolled
- 497
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.